|S A V E T H E D A T E|
|37 DEGREES 2018 LIFE SCIENCE CONFERENCE & EXPO
June 19 – 20, 2018 ° Stavanger Forum,
|° Earn valuable knowledge in the fields of Digitalising healthcare, Digitalisation in biotech and Venture Session
° Over 60 exhibitors from all over the world showcasing the latest innovative products and services from leading companies
° Choose from more than 50 presentations featuring cutting-edge practices in biomedicine and biotechnology
° Network with top professionals in the world
° Take workshop training from leading subject matter experts in the field of life science technologies and innovations
We are excited to introduce you to 37°C in which we will explore and aim to propel the innovations and trends that are shaping the future of healthcare systems and life sciences.
Book your exhibition space now and reserve your prime location in our exhibition area.
The sponsorship opportunities will give you advantage against your competitors. Alternatively, we would be happy to discuss tailor-made sponsorship items to suit your needs.
To learn more, please visit: www.37degreescelsius.net.
For more information, please contact us:
Arne Hansson Rannestad, General Manager, Cell: +47 940 10 236, firstname.lastname@example.org
Hege Kristin Mellemstrand, Project Manager, Cell: +47 913 89 668, email@example.com
Thanks to 2017 Partners
Innovation in the health sector is weak despite a monetary spending of NOK 326 billion. This is the opinion of Abelia which is a branch of the Confederation of Norwegian Enterprise (NHO), who thinks that the Labour Party is more innovative than the Conservative Party and the Progress Party, currently in government.
They are standing in the exhibition hall at the 37 °C health tech conference in Stavanger, trying to convince passers-by of the blessings of the medical technology that they sell.
Air ambulance doctor Nils Petter Oveland (right) had many ideas about how first aid equipment could be improved. The solution was that he linked with British Prometheus Medical Group and top manager Malcolm Russell (left). Photo: Marie von Krogh
Air ambulance doctor Nils Petter Oveland has become an entrepreneur of Prometheus Medical Nordic in addition to his regular work. He no longer is satisfied with writing the research articles the hospital would like to have. He says that he has written five to six such articles, but that there are not many who read them.
– That’s why I became interested in this – because I wanted to influence the treatment of emergency patients. If we have success with our concepts, it will really affect how we treat the patients. That is something that can published instead of research articles.
Complaining about the lack of pace
Oveland is not alone in complaining about the pace of innovation in health care. Even though the spending has increased by 20 percent to NOK 326 billion over the last four years, the health minister Bent Høie (H) is also unhappy with the results. Last week, he stated to this newspaper that there are more pilot[projects]s in health care than in the airline companies Norwegian and SAS combined, but few of them take off and fly, since the healthcare system is not able to change.
Høie is ‘throwing stones in glasshouse’, says Abelia, the association for knowledge and technology companies in NHO.
“It is the minister himself who has the power make the changes,” says Tarje Bjørgum, head of climate and health in Abelia.
He presents whole list of objections. The health system lacks incentives to improve. Refund schemes incentivises yesterday’s solutions. Purchasing schemes do not promote innovation, and leaders are not incentivised to make improvements. The state is development solutions that the market can already offer. The state is also developing huge IT organizations that are not innovative. Norwegian healthcare companies are forced to seek customers abroad, because the home market is not open to innovation.
Minister of health, Bent Høie, visited the 37 °C Life Science Tech Conference on Tuesday, and met Håvard Bakke from Robot Norway.
Minister of health, Bent Høie, believes that the Norwegian health care providers must soon embrace robots and information technology before the demographic wave of elderly people hit us with full force.
He is in the exhibition area at the health technology conference 37 °C in Stavanger and looks at a robot that Håvard Bakke from Robot Norway would like to sell to the health care providers.
Health Minister Bent Høie believes that the implementation of new technology in the health sector that he leads, must go much faster than today.
“I’m getting bored by all the pilot [project]s. I say that in the health service there are more pilots than in the airline companies Norwegian and SAS combined. The challenge is that there are very few of them that actually take off and fly because the health care sector is not able to adapt new technology and improve efficiency, “says Høie.
An example of a pilot project
For example, Høie refers to a pilot project in Stavanger, Oslo and Sarpsborg for the follow-up of chronically ill patients. One of the solutions is that chronically ill patients with lung disease are equipped with technology that allows for the patients to test themselves every day and that gives them feedback on their health conditions.
“It has led to a reduction in the use of hospitals and emergency services and home services of between 20 and 30 percent. It has improved the health of the patients. They say they have better health and better life. So it is a solution that both reduces the need for personnel and improves the health of the patients, “says Høie.
“Using this type of technology is not a pilot project anymore – it has been tested in a number of projects, showing positive results. I hope it will become the new norm.
Robots, not clammy hands
Some of the background for the conference here in Stavanger is that the oil city wants to grow in other sectors now as the oil industry is hit by crisis. Health is a priority area, something everyone from mayor Christine Sagen Helgø to top manager Tore Lærdal in Laerdal Medical talks about at the 37 °C conference in Stavanger Forum. Høie promises plenty of business opportunities for inventive oil technicians that will take on the healthcare industry.
“Yesterday’s solutions are not sustainable in terms of demographic development and disease development. It will require too many people. It is not possible to solve future health challenges in the same way as today, says Høie.
He believes robots for example can do routine tasks and give patients a sense of coping with life.
After the pitching session on June 7th the jury selected Excitus as the winner of the Startup Competition at 37 °C.
The first prize is private meetings with Hadean Ventures and Glenrock Group.
A total of 9 startup submitted their Abstracts in order to take part in the startup competition at 37 °C: AbleOn Medical, iNANOD, CealTech, Dronera, Excitus, MinMemoria, SmartCrowding, PainMonitor, Neuralblock Technology.
iNANOD, Excitus, Dronera and CealTech took part in the pitching session in front of the jury consisting of Henrik Lund / Chairman Oslo Cancer Cluster (Head of Jury), Arve Grude / Senior Manager in EY, Asaf Iram / Investment Manager, GlenRock Group, Sjur Svaboe / Founder and CEO of Biolink Group and Medpalett, Medox, Nadine Sobotzki / Associate with the Life Science Team at MERCK VENTURES, Dan Shwarzman / CEO of MindUP Digital Health Incubator, Walter Stockinger / Dr Managing Partner at Hadean Ventures.
We congratulate Excitus with the victory, thank all startups for participating – and wish all the best of luck!
Co-founder of Excitus, Per Reidar Ørke is congratulated by the Head of the Jury, Henrik Lund, Chairman Oslo Cancer Cluster.
The Day 2 of the First 37 ºC Life Science Technology Conference & Exhibition in Stavanger will start with a greeting from Ruti Alon, Founder and CEO of Medstrada, International Co-Chair of 37 ºC and followed by plenary lecture Nordic Healthtech facts & figures with keynote speakers Erland Skogli, partner in Menon Economics and Anita Kåss, M.D. And Researcher.
Several panel discussions will cover the ‘clinical trials aspects of market entry’, ‘national platforms for innovation’ and ‘how the robots will conquer the world’.
Parallel Sessions provide information for emergency medicine and show us the future with robotics and drones.
The Speakers are:
37 ºC Life Science Technology Conference & Exhibition is the perfect forum for industries to exchange expert ideas and experiences.
JOIN US NOW FOR AN EXCITING CONFERENCE AND EXHIBITION!
The Norwegian Minister of Health, Mr. Bent Høie meets with Arne Hannson Rannestad, General Manager of 37 ºC Life Science Technology Conference & Exhibition, before the opening of the conference.
Today, 06.06.2017, sees the start of the first 37 ºC Life Science Technology Conference & Exhibition in Stavanger. General Manager Arne Hannson Rannestad opens the session by delivering greetings to participants.
The Mayor of Stavanger, Christine Sagen Helgø, welcomes delegates, speakers and sponsors to the first 37 ºC Life Science Technology Conference & Exhibition, an international business platform for industry and innovation.
At 37 ºC Life Science Technology Conference & Exhibition in Stavanger, Ole Petter Ottersen, Rector at University of Oslo, explores the links and similarities between health and oil industry, starting in 1859 with the pioneers Edwin L. Drake (drilling the first well for oil) and Charles Darwin (On the Origin of Species).
Panel discussion covering similarities and differences in how technology is applied and the results achieved. 37 ºC Life Science Technology Conference & Exhibition is the perfect forum for industries to exchange expert ideas and experiences. From the left István Szőke, PhD, Senior Researcher at Institute for Energy Technology / OECD Halden Reactor Project, Thor Adriansen, Manager at Norwegian Competence Centre Helicopter and Tore Lærdal, CEO of Laerdal Medical.
JOIN US NOW FOR AN EXCITING CONFERENCE AND EXHIBITION!
Many #healthcare companies choose #Europe for initial commercialization obtaining CE first prior to US launch due to reduced time and costs to the market.
Germany as the largest European healthcare market offers the perfect platform to gain local evidence and roll out the concept into the other EU markets. However, for foreign companies it is difficult to understand the critical regulatory and marketing roadmaps leading to a successful introduction of a product in Germany and Europe.
Foreign companies often require an experienced team to drive the process from clinical development to commercialization. Hannover Clinical Trial Center (HCTC) and its partner mediq Innovation Experts have established a streamlined program to support foreign medtech or biotech companies for their early entry into Germany and Europe. This program has already shown a successful implementation in terms of successful market entry of products from international companies.
Our hub provides a single source of support with a successful track record of more than 11 years experience and over 15 successful technology introductions. In the past, we have supported various international companies by:
- Defining the business opportunity in Europe
- Developing both the local clinical and business strategy
- Determining and allocating key opinion leaders as well as clinical centers
- Identifying, assigning, and supporting the best matching commercial partner
Meet with Us at #37°C Life Science Technology Conference & Exhibition
Jan Wende (mediq Innovation Experts) and Prof. Heiko von der Leyen (Hannover Clinical Trial Center) will be holding a panel together at 37 °C. We are looking forward to meeting you in Stavanger next week.
Mediq is a strategy and innovation consulting firm for the German, European and Israel markets. The company specializes in supporting strategic vision, clinical validation, market assessment and development, for companies focused on approval and commercialization of biomed/lifescience products into the European market.
Hannover Clinical Trial Center, founded in 2005, is an academic Contract Research Organization dedicated to provide clinical trial management services and early product development support. HCTC combines the clinical expertise and academic leadership of Hannover Medical School, a premier German university hospital, with the full-service operational capabilities of a contract research organization.
For more information and registrations:
CEO, EXCELLER AS
Mob: +47 940 10 236
Development of the 37 ºC Life Science Technology Conference & Exhibition 6th-7th June 2017 Stavanger Forum in Norway is in partnership with Stavanger Forum and Kenes Exhibitions.
Please Register Today: Click Here
Order your exhibition space: Click Here
Enter into Partnership with us: Click Here
The Norwegian company Cealtech will start production of graphene – a material that can be important in everything from oil and gas to electronics, solar, medicine and spacecraft.
“It sounds like a material that will be a major revolution for new material technologies in the future,” says Prime Minister of Norway, Erna Solberg.
She newly met the Norwegian company that will soon mass-produce the super material graphene – known to be the thinnest and strongest material that has been created, with the potential to revolutionize a number of industries.
After the meeting Solberg said that it is important that we are able to develop new technologies.
“Norway is a country that is very good at material technology. It has been a priority since the early 80’s.
The material with a number of unusual characteristics, one of them being that it is 200 times stronger than steel, but very flexible, was first isolated by physicists Andre Geim and Konstantin Novoselov in 2004 – with the help of a fairly common piece of tape and graphite.
The two later won the Nobel Prize in Physics for their work with graphene.
The structure of the material is only one atom thick, based on carbon-shape graphite, with qualities that allow applications that span from industries such as oil and gas to electronics, solar, medicine and spacecraft.
– It’s a supermaterial. If we can find large-volume applications for graphene at sufficiently low prices, we will enter into a new age, says Lars Helge Helvig.
He is the largest owner and Acting General Manager of the Stavanger-based company Cealtech.
Prime Minister Erna Solberg met Cealtech in Oslo last Tuesday. From right: David Boyd at Caltech University, Technical Manager Marius Andreassen Jakobsen in Cealtech and Acting General Manager in Cealtech, Lars Helge Helvig.
Dagens Næringsliv; www.dn.no; firstname.lastname@example.org
Cancer in the family led Bjørn Rune Gjelsten into ownership in the cancer vaccine company Ultimovacs. The company is now attracting interest from “big pharma” players and the company valuation is approaching 1 billion NOK.
Bjørn Rune Gjelsten had a personal reason to go into Ultimovacs. Now, the company that develops cancer vaccine based on immunotherapy can also prove to be a very good investment.
“The reason I entered was that I had cancer in my family. My father got sick and I got in touch with an environment around the Radium Hospital, says Gjelsten, who lost his father with prostate diagnosis a couple of years ago.
The company was in an early phase and faced a capital tire. So far, Gjelsten has invested NOK 30 million.
“Although I had a personal entrance, it’s no more money than it would be okay to lose,” he says.
As the development of the vaccine goes through different phases, the value of Ultimovacs also rises. Gjelsten Holding holds 35 percent of the shares.
“Now there is interest from large industrial players from big pharma and the Norwegian investor communities.
Strengthens the immune system
By means of immunotherapy, the body will be equipped to to fight the cancer cells.
One of the unanswered questions is how the vaccine works in combination with other medications in order to attack the cancer cells. This has aroused the interest of pharmaceutical companies with well-established cancer medicine. Immunotherapy and traditional medicine can attack the cancer from two angles, so-called duo treatment.
“The traditional medicine may weaken and passivate the cancer, while immunotherapy activates the immune system so that the body may attack the cancer by itself.
A real breakthrough will be if the vaccine can be used preventively against vulnerable groups.
– US authorities are now looking into whether the vaccine can be used proactively, Gjelsten adds.
Stock exchange for similar company
Ultimovacs is compared to another fast-growing immunotherapy company, Targovax, which has already reached a face value of NOK 1.1 billion on the stock exchange. The share price of Targovax has risen 120 percent since January last year.
Jonas Einarsson, Managing Director of the Radium Hospital Research Foundation, believes the two companies have clear resemblances and confirm that immunotherapy vaccines developed in Norway have become interesting for drug giants.
– The Vaccines that these two companies develop are made on the same platform, but have different types of attacks. I have to say that the clinical results are encouraging, but it takes time. I am an optimist for both companies, says Einarsson, who is in the board of both companies.
Ultimovacs will give a presentation in the Conference Program at 37 °C,
on June 6th.